Affimed (NASDAQ:AFMD – Get Free Report) and Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.
Risk & Volatility
Affimed has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500.
Profitability
This table compares Affimed and Mineralys Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Affimed | -2,361.94% | -135.81% | -87.96% |
| Mineralys Therapeutics | N/A | -32.48% | -31.10% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Affimed | $8.95 million | 9.09 | -$114.66 million | N/A | N/A |
| Mineralys Therapeutics | N/A | N/A | -$71.90 million | ($2.19) | -5.51 |
Mineralys Therapeutics has lower revenue, but higher earnings than Affimed.
Analyst Ratings
This is a summary of current ratings and price targets for Affimed and Mineralys Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Affimed | 0 | 0 | 6 | 0 | 3.00 |
| Mineralys Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
Affimed presently has a consensus price target of $41.67, indicating a potential upside of 677.36%. Mineralys Therapeutics has a consensus price target of $33.50, indicating a potential upside of 179.87%. Given Affimed’s higher probable upside, analysts clearly believe Affimed is more favorable than Mineralys Therapeutics.
Insider & Institutional Ownership
30.8% of Affimed shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 3.8% of Affimed shares are owned by insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Mineralys Therapeutics beats Affimed on 6 of the 10 factors compared between the two stocks.
About Affimed
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
About Mineralys Therapeutics
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.
